Close Menu

NEW YORK – ArcherDx said on Friday that it has signed a non-exclusive, multiyear partnership with Illumina intended to broaden access to next-generation sequencing oncology testing, including — upon regulatory approval — companion diagnostics for therapeutic selection, personalized monitoring, and new recurrence surveillance in vitro diagnostics.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.